Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Fujisawa antifungal gets FDA OK
The newly approved agent will be marketed in the US under the name Mycamine (micafungin sodium for injection). The approval is based on 32 clinical studies conducted in
The newly approved agent will be marketed in the US under the name Mycamine (micafungin sodium for injection). The approval is based on 32 clinical studies conducted in
Symlin (pramlintide acetate) injection will be used at mealtime in patients with type 2 or type 1 diabetes who have failed to achieve desired glucose control despite optimal
The approval was based on data that demonstrated a significant overall survival benefit in patients who were treated with Temodar(temozolomide) in combination with radiotherapy. Concurrent with the approval
The company’s clinical program for AMD070 is being conducted by leading investigators at the US Adult AIDS Clinical Trials Group (ACTG), which is supported by the National Institute
In the expanded partnership, OncoGenex will be solely responsible for the preclinical and clinical development of the added anticancer drugs. OncoGenex will pay Isis an upfront fee, milestone
The National Cancer Institute (NCI) findings in osteosarcoma, a form of bone cancer, are consistent with a preclinical study of CTCE-9908 conducted by researchers at Chemokine Therapeutics. CTCE-9908
The serious adverse events involved apparent lactic acidosis, a dangerous buildup of lactic acid. The two patients concerned were administered CS-917 in combination with metformin, which has itself
This is the first time a leading cosmetic brand and a prestigious medical institution such as Weill Cornell have collaborated on an initiative that addresses skin wellness from
The withdrawal of Tysabri after the drug was linked to a fatal brain disease, which was shortly followed by the resignation of Biogen Idec’s general counsel, has prompted
Under the terms of the agreement, Altana Pharma will supply Cyclacel with selected experimental molecules shown to interfere with mitosis (cell division). Scientists at Cyclacel’s Polgen Division in